{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:31:04Z","timestamp":1787671864099,"version":"build-2736575974"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":70,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Research Fund, 2025 of The Catholic University of Korea."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"DOI":"10.1186\/s12962-026-00787-0","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:46:45Z","timestamp":1781610405000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring trends of cost-effectiveness thresholds in South Korea: systematic review of pharmacoeconomic evaluations since introduction of the positive list system"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1653-1672","authenticated-orcid":false,"given":"Hyun-ji","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5385-9685","authenticated-orcid":false,"given":"Kyung-ae","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6220-7635","authenticated-orcid":false,"given":"Suk-Chan","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9616-3179","authenticated-orcid":false,"given":"Kyung Ah","family":"Ban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0601-7754","authenticated-orcid":false,"given":"Eui-Kyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4421-4513","authenticated-orcid":false,"given":"Sun-Kyeong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"787_CR1","doi-asserted-by":"publisher","first-page":"1449707","DOI":"10.3389\/fpubh.2024.1449707","volume":"12","author":"A Vallano","year":"2024","unstructured":"Vallano A, Pontes C. Escalating costs of innovative medicines: perspective and proposals. Front Public Health. 2024;12:1449707.","journal-title":"Front Public Health"},{"key":"787_CR2","unstructured":"National Institute for Health and Care Excellence (NICE). NICE health technology evaluations: the manual. London: NICE; 2022. PMCID: PMC10549442."},{"key":"787_CR3","unstructured":"Health Insurance Review and Assessment Service (HIRA). Drug economic evaluation guidelines. Wonju: HIRA; 2021Drug economic evaluation guidelines. https:\/\/www.hira.or.kr\/bbsDummy.do?pgmid=HIRAA020002000100&brdScnBltNo=4&brdBltNo=8661#none."},{"key":"787_CR4","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2471\/BLT.15.164418","volume":"94","author":"MY Bertram","year":"2016","unstructured":"Bertram MY, Lauer JA, De Joncheere K, Edejer T, Hutubessy R, Kieny MP, Hill SR. Cost-effectiveness thresholds: pros and cons. Bull World Health Organ. 2016;94:925\u201330.","journal-title":"Bull World Health Organ"},{"key":"787_CR5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jval.2021.08.014","volume":"25","author":"J Kazibwe","year":"2022","unstructured":"Kazibwe J, Gheorghe A, Wilson D, Ruiz F, Chalkidou K, Chi YL. The Use of Cost-Effectiveness Thresholds for Evaluating Health Interventions in Low- and Middle-Income Countries From 2015 to 2020: A Review. Value Health. 2022;25:385\u20139.","journal-title":"Value Health"},{"key":"787_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta19140","volume":"19","author":"K Claxton","year":"2015","unstructured":"Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, Devlin N, Smith PC, Sculpher M. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess. 2015;19:1\u2013v503.","journal-title":"Health Technol Assess"},{"key":"787_CR7","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s40258-022-00730-3","volume":"20","author":"C Sampson","year":"2022","unstructured":"Sampson C, Zamora B, Watson S, Cairns J, Chalkidou K, Cubi-Molla P, Devlin N, Garc\u00eda-Lorenzo B, Hughes DA, Leech AA, Towse A. Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy. Appl Health Econ Health Policy. 2022;20:651\u201367.","journal-title":"Appl Health Econ Health Policy"},{"key":"787_CR8","doi-asserted-by":"publisher","first-page":"104963","DOI":"10.1016\/j.healthpol.2023.104963","volume":"139","author":"M Sellars","year":"2024","unstructured":"Sellars M, Carter SM, Lancsar E, Howard K, Coast J. Making recommendations to subsidize new health technologies in Australia: A qualitative study of decision-makers\u2019 perspectives on committee processes. Health Policy. 2024;139:104963.","journal-title":"Health Policy"},{"key":"787_CR9","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1001\/jama.2009.1409","volume":"302","author":"FM Clement","year":"2009","unstructured":"Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA. 2009;302:1437\u201343.","journal-title":"JAMA"},{"key":"787_CR10","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2217\/cer.15.38","volume":"4","author":"R Schwarzer","year":"2015","unstructured":"Schwarzer R, Rochau U, Saverno K, Jahn B, Bornschein B, Muehlberger N, Flatscher-Thoeni M, Schnell-Inderst P, Sroczynski G, Lackner M, et al. Systematic overview of cost-effectiveness thresholds in ten countries across four continents. J Comp Eff Res. 2015;4:485\u2013504.","journal-title":"J Comp Eff Res"},{"key":"787_CR11","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jval.2016.08.726","volume":"20","author":"T Shiroiwa","year":"2017","unstructured":"Shiroiwa T, Fukuda T, Ikeda S, Takura T, Moriwaki K. Development of an official guideline for the economic evaluation of drugs\/medical devices in Japan. Value Health. 2017;20:372\u20138.","journal-title":"Value Health"},{"key":"787_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jval.2019.10.005","volume":"23","author":"M Hasegawa","year":"2020","unstructured":"Hasegawa M, Komoto S, Shiroiwa T, Fukuda T. Formal Implementation of Cost-Effectiveness Evaluations in Japan: A Unique Health Technology Assessment System. Value Health. 2020;23:43\u201351.","journal-title":"Value Health"},{"key":"787_CR13","doi-asserted-by":"publisher","unstructured":"Xu L, Chen M, Angell B, Jiang Y, Howard K, Jan S, Si L. Establishing cost-effectiveness threshold in China: a community survey of willingness to pay for a healthy life year. BMJ Glob Health. 2024;9(1):e013070. PMCID: PMC10806867. https:\/\/doi.org\/10.1136\/bmjgh-2023-013070.","DOI":"10.1136\/bmjgh-2023-013070"},{"key":"787_CR14","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s10198-021-01384-z","volume":"23","author":"D Cai","year":"2022","unstructured":"Cai D, Shi S, Jiang S, Si L, Wu J, Jiang Y. Estimation of the cost-effective threshold of a quality-adjusted life year in China based on the value of statistical life. Eur J Health Econ. 2022;23:607\u201315.","journal-title":"Eur J Health Econ"},{"issue":"Suppl 3","key":"787_CR15","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1111\/j.1524-4733.2009.00625.x","volume":"12","author":"EY Bae","year":"2009","unstructured":"Bae EY, Lee EK. Pharmacoeconomic guidelines and their implementation in the positive list system in South Korea. Value Health. 2009;12(Suppl 3):S36\u201341.","journal-title":"Value Health"},{"key":"787_CR16","unstructured":"Ministry of Health and Welfare. Pharmaceutical pricing system reform to improve patient access and promote pharmaceutical innovation [Internet]. Sejong: Ministry of Health and Welfare; 2026 Mar 26. Available from: https:\/\/www.mohw.go.kr\/board.es?mid=a10503010100&bid=0027&act=view&list_no=1489840."},{"key":"787_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.18553\/jmcp.2003.9.1.53","volume":"9","author":"JJ Ofman","year":"2003","unstructured":"Ofman JJ, Sullivan SD, Neumann PJ, Chiou C-F, Henning JM, Wade SW, Hay JW. Examining the Value and Quality of Health Economic Analyses: Implications of Utilizing the QHES. J Managed Care Pharm. 2003;9:53\u201361.","journal-title":"J Managed Care Pharm"},{"key":"787_CR18","first-page":"1249","volume":"52","author":"HY Kang","year":"2009","unstructured":"Kang HY, Kim D, Sewon Yang Y, Kim M-S, Kim. Economic evaluation of a weekly administration of a sustained-release injection of recombinant human growth hormone for the treatment of children with growth hormone deficiency. Clin Experimental Pediatr (CEP). 2009;52:1249\u201359.","journal-title":"Clin Experimental Pediatr (CEP)"},{"key":"787_CR19","first-page":"96","volume":"19","author":"K-H Hyuntaek Shin","year":"2009","unstructured":"Hyuntaek Shin K-H, Lim, Son H, Jungmi Oh Y-S, Lee. Cost-Effectiveness Analysis of Glimepiride or Pioglitazone in Combination with Metformin in Type-2 Diabetic Patients. Korean Soc Clin Pharm. 2009;19:96\u2013104.","journal-title":"Korean Soc Clin Pharm"},{"key":"787_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3350\/kjhep.2009.15.1.25","volume":"15","author":"BK Kim","year":"2009","unstructured":"Kim BK, Kwon SY, Lee CH, Choe WH, Choi HM, Koo HW. Analysis of the cost-effectiveness of antiviral therapies in chronic hepatitis B patients in Korea. Korean J Hepatol. 2009;15:25\u201341.","journal-title":"Korean J Hepatol"},{"key":"787_CR21","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1111\/j.1524-4733.2009.00633.x","volume":"12","author":"J Kim","year":"2009","unstructured":"Kim J, Kim Y. A time-cost augmented economic evaluation of oral deferasirox versus infusional dereroxmine for patients with iron overload in South Korea. Value Health. 2009;12:S78\u201381.","journal-title":"Value Health"},{"key":"787_CR22","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1111\/j.1524-4733.2009.00628.x","volume":"12","author":"KH Lee","year":"2009","unstructured":"Lee KH, Seo SJ, Smith-Palmer J, Palmer JL, White J, Valentine WJ. Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea. Value Health. 2009;12:S55\u201361.","journal-title":"Value Health"},{"key":"787_CR23","first-page":"93","volume":"17","author":"YK Lee","year":"2009","unstructured":"Lee YK, Bae S-C, Yoon-Kyung Sung S, Ko. Cost-effectiveness of early use of etanercept in the treatment of rheumatoid arthritis. Translational Clin Pharmacol. 2009;17:93\u2013106.","journal-title":"Translational Clin Pharmacol"},{"key":"787_CR24","first-page":"260","volume":"23","author":"N-K Kim","year":"2010","unstructured":"Kim N-K, Oh Y-L, Seo E-S, Lee D-H. Cost-effectiveness Analysis of Bojungikgitang and Banhabaekchulchonmatang in Chronic Tinnitus Patients. J Orient Otolaryngol Dermatology. 2010;23:260\u20139.","journal-title":"J Orient Otolaryngol Dermatology"},{"key":"787_CR25","doi-asserted-by":"publisher","first-page":"286","DOI":"10.4048\/jbc.2010.13.3.286","volume":"13","author":"HJ Lee","year":"2010","unstructured":"Lee HJ, Lee TJ, Yang BM, Min J. Cost-effectiveness analysis of adjuvant hormonal treatments for women with postmenopausal hormone-receptor positive early breast cancer in the Korean context. J Breast Cancer. 2010;13:286\u201398.","journal-title":"J Breast Cancer"},{"key":"787_CR26","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2147\/CEOR.S42170","volume":"5","author":"HY Lee","year":"2013","unstructured":"Lee HY, Yang BM, Hong JM, Lee TJ, Kim BG, Kim JW, Kim YT, Kim YM, Kang S. Cost-utility analysis for platinum-sensitive recurrent ovarian cancer therapy in South Korea: Results of the polyethylene glycolated liposomal doxorubicin\/carboplatin sequencing model. ClinicoEconomics Outcomes Res. 2013;5:297\u2013307.","journal-title":"ClinicoEconomics Outcomes Res"},{"key":"787_CR27","doi-asserted-by":"publisher","first-page":"8503","DOI":"10.7314\/APJCP.2014.15.19.8503","volume":"15","author":"KT Han","year":"2014","unstructured":"Han KT, Kim SJ, Lee SY, Park EC. Cost-effectiveness analysis of HPV vaccination: comparing the general population with socially vulnerable individuals. Asian Pac J cancer prevention: APJCP. 2014;15:8503\u20138.","journal-title":"Asian Pac J cancer prevention: APJCP"},{"key":"787_CR28","doi-asserted-by":"crossref","first-page":"124","DOI":"10.34161\/johta.2014.2.2.007","volume":"2","author":"J Kim","year":"2014","unstructured":"Kim J, Oh Y, Kim J-D. Cost-Effectiveness of Dabigatran Etexilate versus Warfarin for the Prevention of Stroke and Systemic Embolism in Korea Patients with Non-Valvular Atrial Fibrillation. Korean Soc Healthc Technol Assess. 2014;2:124\u20139.","journal-title":"Korean Soc Healthc Technol Assess"},{"key":"787_CR29","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.clinthera.2014.07.010","volume":"36","author":"MY Lee","year":"2014","unstructured":"Lee MY, Kang HJ, Park SY, Kim HL, Han E, Lee EK. Cost-effectiveness of tolvaptan for euvolemic or hypervolemic hyponatremia. Clin Ther. 2014;36:1183\u201394.","journal-title":"Clin Ther"},{"key":"787_CR30","doi-asserted-by":"publisher","unstructured":"Lim EA, Sohn HS, Lee H, Choi SE. Cost-utility of ferric carboxymaltose (Ferinject\u00ae) for iron-deficiency anemia patients with chronic heart failure in South Korea. Cost Eff Resour Alloc. 2014;12:21. PMCID: PMC4192437. https:\/\/doi.org\/10.1186\/1478-7547-12-21.","DOI":"10.1186\/1478-7547-12-21"},{"key":"787_CR31","first-page":"25","volume":"20","author":"Y Kim","year":"2014","unstructured":"Kim Y, Kim E, Park D-J. Economic Evaluation of Varenicline and an Existing Smoking Cessation strategy in Korea. Health Econ Policy Res. 2014;20:25\u201344.","journal-title":"Health Econ Policy Res"},{"key":"787_CR32","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1016\/j.clinthera.2015.07.001","volume":"37","author":"MY Lee","year":"2015","unstructured":"Lee MY, Park SK, Park SY, Byun JH, Lee SM, Ko SK, Lee EK. Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea. Clin Ther. 2015;37:1662\u201376.","journal-title":"Clin Ther"},{"key":"787_CR33","unstructured":"Kim Y. Economic analysis of the HPV vaccine. In: Proceedings of the Korean Society of Health Administration Fall Conference; 2015 Oct 30-31; Seoul, South Korea. Seoul: Korean Society of Health Administration; 2015. p. 381-413."},{"key":"787_CR34","doi-asserted-by":"publisher","first-page":"63","DOI":"10.11005\/jbm.2016.23.2.63","volume":"23","author":"JW Kwon","year":"2016","unstructured":"Kwon JW, Park HY, Kim YJ, Moon SH, Kang HY. Cost-effectiveness of Pharmaceutical Interventions to Prevent Osteoporotic Fractures in Postmenopausal Women with Osteopenia. J Bone Metab. 2016;23:63\u201377.","journal-title":"J Bone Metab"},{"key":"787_CR35","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.clinthera.2016.01.023","volume":"38","author":"HY Park","year":"2016","unstructured":"Park HY, Ku HM, Sohn HS, Seo HS, Yung Lee H, Hwa Lim K, Kwon JW. Cost-effectiveness of Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the Republic of Korea. Clin Ther. 2016;38:655\u2013e667652.","journal-title":"Clin Ther"},{"key":"787_CR36","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1016\/j.clinthera.2016.09.016","volume":"38","author":"SK Park","year":"2016","unstructured":"Park SK, Park SH, Lee MY, Park JH, Jeong JH, Lee EK. Cost-effectiveness Analysis of Treatment Sequence Initiating With Etanercept Compared With Leflunomide in Rheumatoid Arthritis: Impact of Reduced Etanercept Cost With Patent Expiration in South Korea. Clin Ther. 2016;38:2430\u201346.","journal-title":"Clin Ther"},{"key":"787_CR37","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2147\/CEOR.S110553","volume":"8","author":"G Tremblay","year":"2016","unstructured":"Tremblay G, Majethia U, Breeze JL, Kontoudis I, Park J. Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea. ClinicoEconomics Outcomes Res. 2016;8:485\u201393.","journal-title":"ClinicoEconomics Outcomes Res"},{"key":"787_CR38","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s40258-017-0317-y","volume":"15","author":"DJ Kim","year":"2017","unstructured":"Kim DJ, Kim HS, Oh M, Kim EY, Shin JG. Cost Effectiveness of Genotype-Guided Warfarin Dosing in Patients with Mechanical Heart Valve Replacement Under the Fee-for-Service System. Appl Health Econ Health Policy. 2017;15:657\u201367.","journal-title":"Appl Health Econ Health Policy"},{"key":"787_CR39","doi-asserted-by":"publisher","first-page":"131","DOI":"10.24304\/kjcp.2018.28.2.131","volume":"28","author":"G Bae","year":"2018","unstructured":"Bae G, Kwon H-Y. Cost-Effectiveness of Denosumab for Post-Menopausal Osteoporosis in South Korea. J Korean Soc Clin Pharmacol. 2018;28:131\u20137.","journal-title":"J Korean Soc Clin Pharmacol"},{"key":"787_CR40","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.clinthera.2017.02.005","volume":"40","author":"JH Cho","year":"2018","unstructured":"Cho JH, Jang HM, Jung HY, Choi JY, Park SH, Kim CD, Yang CW, Jin DC, Kim YL. A Real-world Cost-effectiveness Analysis of Sevelamer Versus Calcium Acetate in Korean Dialysis Patients. Clin Ther. 2018;40:123\u201334.","journal-title":"Clin Ther"},{"key":"787_CR41","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1080\/21645515.2018.1456602","volume":"14","author":"MJ Choi","year":"2018","unstructured":"Choi MJ, Kang SO, Oh JJ, Park SB, Kim MJ, Cheong HJ. Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in south Korea. Hum Vaccines Immunotherapeutics. 2018;14:1914\u201322.","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"787_CR42","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1007\/s40273-018-0715-5","volume":"36","author":"YK Kim","year":"2018","unstructured":"Kim YK, Song JY, Jang H, Kim TH, Koo H, Varghese L, Han E. Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea. PharmacoEconomics. 2018;36:1475\u201390.","journal-title":"PharmacoEconomics"},{"key":"787_CR43","doi-asserted-by":"publisher","unstructured":"Lee D, Shin HY, Park SM. Cost-effectiveness of antiviral prophylaxis during pregnancy for the prevention of perinatal hepatitis B infection in South Korea. Cost Eff Resour Alloc. 2018;16:5. PMCID: PMC5819207. https:\/\/doi.org\/10.1186\/s12962-018-0088-9.","DOI":"10.1186\/s12962-018-0088-9"},{"key":"787_CR44","first-page":"409","volume":"35","author":"M Suji Kwon","year":"2018","unstructured":"Suji Kwon M, Geum, Kim J-S, Eunseon Son. Kyunghee Kwon: Cost-Utility Analysis of Pegfilgrastim and Pegteograstim in Patients with Breast Cancer using Doxorubicin and Cyclophosphamide. Hosp Pharm J. 2018;35:409\u201317.","journal-title":"Hosp Pharm J"},{"key":"787_CR45","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/21645515.2017.1362513","volume":"14","author":"XH Zhang","year":"2018","unstructured":"Zhang XH, Leeuwenkamp O, Oh KB, Lee YE, Kim CM. Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea. Hum Vaccines Immunotherapeutics. 2018;14:85\u201394.","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"787_CR46","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/jgh.14554","volume":"34","author":"W Chung","year":"2019","unstructured":"Chung W, Kim KA, Jang ES, Ki M, Choi HY, Jeong SH. Cost-effectiveness of sofosbuvir plus ribavirin therapy for hepatitis C virus genotype 2 infection in South Korea. J Gastroenterol Hepatol (Australia). 2019;34:776\u201383.","journal-title":"J Gastroenterol Hepatol (Australia)"},{"key":"787_CR47","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1080\/03007995.2019.1605159","volume":"35","author":"S Han","year":"2019","unstructured":"Han S, Kim S, Kim H, Suh HS. Cost\u2013utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting \u03b22-agonists in South Korea. Curr Med Res Opin. 2019;35:1597\u2013605.","journal-title":"Curr Med Res Opin"},{"key":"787_CR48","doi-asserted-by":"publisher","first-page":"252","DOI":"10.4070\/kcj.2018.0220","volume":"49","author":"H Kim","year":"2019","unstructured":"Kim H, Kim H, Cho SK, Kim JB, Joung B, Kim C. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Korean Circulation J. 2019;49:252\u201363.","journal-title":"Korean Circulation J"},{"key":"787_CR49","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3349\/ymj.2019.60.12.1157","volume":"60","author":"M Kim","year":"2019","unstructured":"Kim M, Kim W, Kim C, Joung B. Cost-effectiveness of rate- and rhythm-control drugs for treating atrial fibrillation in Korea. Yonsei Med J. 2019;60:1157\u201363.","journal-title":"Yonsei Med J"},{"key":"787_CR50","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.clinthera.2019.04.031","volume":"41","author":"SK Park","year":"2019","unstructured":"Park SK, Hong SH, Kim H, Kim S, Lee EK. Cost-Utility Analysis of Sacubitril\/Valsartan Use Compared With Standard Care in Chronic Heart Failure Patients With Reduced Ejection Fraction in South Korea. Clin Ther. 2019;41:1066\u201379.","journal-title":"Clin Ther"},{"key":"787_CR51","doi-asserted-by":"publisher","unstructured":"Yun JW, Choi MJ, Shin GS, Lim JO, Noh JY, Kim YK, Song JY, Kim WJ, Choi SE, Cheong HJ. Cost-effectiveness of influenza vaccine strategies for the elderly in South Korea. PLoS One. 2019;14(10):e0224283. PMCID: PMC6812833. https:\/\/doi.org\/10.1371\/journal.pone.0224283.","DOI":"10.1371\/journal.pone.0224283"},{"key":"787_CR52","doi-asserted-by":"publisher","first-page":"5002","DOI":"10.1016\/j.vaccine.2020.05.065","volume":"38","author":"EJ Choi","year":"2020","unstructured":"Choi EJ, Park JH, Chun BC. Cost effectiveness of trivalent and quadrivalent influenza vaccines in 50- to 64-year-old adults in Korea. Vaccine. 2020;38:5002\u20138.","journal-title":"Vaccine"},{"key":"787_CR53","doi-asserted-by":"publisher","first-page":"14609","DOI":"10.1038\/s41598-020-71565-y","volume":"10","author":"H Choi","year":"2020","unstructured":"Choi H, Suh J, Lee W, Kim JH, Kim JH, Seong H, Ahn JY, Jeong SJ, Ku NS, Park YS, et al. Cost-effectiveness analysis of pre-exposure prophylaxis for the prevention of HIV in men who have sex with men in South Korea: a mathematical modelling study. Sci Rep. 2020;10:14609.","journal-title":"Sci Rep"},{"key":"787_CR54","doi-asserted-by":"publisher","unstructured":"Park S, Kim AY, Cho H, Baik D, Lee H, Cho S, Kang HY. Cost-utility analysis of pralatrexate for relapsed or refractory peripheral T-cell lymphoma based on a case-matched historical control study along with single arm clinical trial. BMC Cancer. 2020 Nov 26;20(1):1157. PMCID: PMC7690091. https:\/\/doi.org\/10.1186\/s12885-020-07629-z.","DOI":"10.1186\/s12885-020-07629-z"},{"key":"787_CR55","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s40744-021-00278-z","volume":"8","author":"SY Ha","year":"2021","unstructured":"Ha SY, Shim YB, Lee MY, Koo BS, Kim JH, Jeon JY, Yoo HJ, Kim YJ, Shin JY, Park MH. Comparative Cost-Effectiveness of Tofacitinib With Continuing Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for Active Rheumatoid Arthritis in South Korea. Rheumatol Therapy. 2021;8:395\u2013409.","journal-title":"Rheumatol Therapy"},{"key":"787_CR56","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/j.jaip.2020.11.052","volume":"9","author":"SH Hong","year":"2021","unstructured":"Hong SH, Cho JY, Kim TB, Lee EK, Kwon SH, Shin JY. Cost-Effectiveness of Tiotropium in Elderly Patients with Severe Asthma Using Real-World Data. J Allergy Clin Immunology: Pract. 2021;9:1939\u201347. e1937.","journal-title":"J Allergy Clin Immunology: Pract"},{"key":"787_CR57","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1080\/21645515.2020.1796426","volume":"17","author":"HY Kim","year":"2021","unstructured":"Kim HY, Park SB, Kang ES, Lee SM, Kim HJ, Wasserman M. Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea. Hum Vaccines Immunotherapeutics. 2021;17:909\u201318.","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"787_CR58","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s40258-021-00640-w","volume":"19","author":"S Kim","year":"2021","unstructured":"Kim S, Han S, Kim H, Suh HS. Cost-Effectiveness and Value of Information of Cabozantinib Treatment for Patients with Advanced Renal Cell Carcinoma After Failure of Prior Therapy in South Korea. Appl Health Econ Health Policy. 2021;19:545\u201355.","journal-title":"Appl Health Econ Health Policy"},{"key":"787_CR59","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1111\/hae.14143","volume":"27","author":"H Lee","year":"2021","unstructured":"Lee H, Cho H, Han JW, Kim AY, Park S, Lee M, Cho S, Baik D, Kang HY. Cost-utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea. Haemophilia. 2021;27:e12\u201321.","journal-title":"Haemophilia"},{"key":"787_CR60","doi-asserted-by":"publisher","first-page":"E00299","DOI":"10.14309\/ctg.0000000000000299","volume":"12","author":"H Lee","year":"2021","unstructured":"Lee H, Kim BK, Jang S, Ahn SH. Cost-Effectiveness Analysis of Antiviral Therapy for Untreated Minimally Active Chronic Hepatitis B to Prevent Liver Disease Progression. Clin Translational Gastroenterol. 2021;12:E00299.","journal-title":"Clin Translational Gastroenterol"},{"key":"787_CR61","doi-asserted-by":"publisher","unstructured":"Choi JH, Kim W, Kim YT, Cho J, Shin SY, Kim C, Kim JB. Cost-effectiveness of Direct Oral Anticoagulant vs. Warfarin Among Atrial Fibrillation Patients With Intermediate Stroke Risk. Front Cardiovasc Med. 2022 Apr 11;9:849474. PMCID: PMC9035745. https:\/\/doi.org\/10.3389\/fcvm.2022.849474.","DOI":"10.3389\/fcvm.2022.849474"},{"key":"787_CR62","doi-asserted-by":"publisher","first-page":"83","DOI":"10.11005\/jbm.2022.29.2.83","volume":"29","author":"K Jung-Yoon","year":"2022","unstructured":"Jung-Yoon K, Leejung C, Ben J, Hyowon Y. Cost-Effectiveness of Denosumab for the Treatment of Postmenopausal Osteoporosis in South Korea. J Korean Soc Bone Metabolism. 2022;29:83\u201392.","journal-title":"J Korean Soc Bone Metabolism"},{"key":"787_CR63","doi-asserted-by":"publisher","unstructured":"Lee JE, Jung IC, Lee SY, Lim JH, Kim BK, Cho E. The Cost-Effectiveness Analysis of Gamiguibi-Tang versus Hwangryunhaedok-Tang for Patients with Insomnia Disorder Based on a Randomized Controlled Trial. Healthcare (Basel). 2022 Oct 26;10(11):2157. PMC9690131. https:\/\/doi.org\/10.3390\/healthcare10112157.","DOI":"10.3390\/healthcare10112157"},{"key":"787_CR64","first-page":"198","volume":"3","author":"D Hwang","year":"2023","unstructured":"Hwang D, Kim HL, Koo BK, Rhee TM, Yang DW, Seo Y, Byun J, Kang J, Han JK, Park KW, et al. Cost-Effectiveness of Clopidogrel vs Aspirin Monotherapy After Percutaneous Coronary Intervention: Results From the HOST-EXAM Study. JACC: Asia. 2023;3:198\u2013207.","journal-title":"JACC: Asia"},{"key":"787_CR65","doi-asserted-by":"publisher","first-page":"e250","DOI":"10.3346\/jkms.2023.38.e250","volume":"38","author":"Y Jo","year":"2023","unstructured":"Jo Y, Kim SB, Jung J. A Model-Based Cost-Effectiveness Analysis of Long-Acting Monoclonal Antibody (Tixagevimab and Cilgavimab: Evusheld) Preventive Treatment for High-Risk Populations Against SARS-CoV-2 in Korea. J Korean Med Sci. 2023;38:e250.","journal-title":"J Korean Med Sci"},{"key":"787_CR66","doi-asserted-by":"publisher","unstructured":"Lee JE, Kang HW, Jung SA, Lee SY, Kim JY, Lee DE, Jeong JH, Jung IC, Cho E. The effects of herbal medicine (Jujadokseo-hwan) on quality of life in patients with mild cognitive impairment: cost-effectiveness analysis alongside randomized controlled trial. Integr Med Res. 2023 Mar;12(1):100914. PMCID: PMC9826841. https:\/\/doi.org\/10.1016\/j.imr.2022.100914.","DOI":"10.1016\/j.imr.2022.100914"},{"key":"787_CR67","doi-asserted-by":"publisher","unstructured":"Nham E, Seong H, Hyun H, Yoon JG, Noh JY, Cheong HJ, Kim WJ, Kim E, Choi L, Lee JM, Song JY. Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate. Hum Vaccin Immunother. 2023 Dec 31;19(1):2212328. https:\/\/doi.org\/10.1080\/21645515.2023.2212328.","DOI":"10.1080\/21645515.2023.2212328"},{"key":"787_CR68","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.vaccine.2024.01.031","volume":"42","author":"DW Kang","year":"2024","unstructured":"Kang DW, Kim CR, Song JY, Park SK. Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea. Vaccine. 2024;42:871\u20138.","journal-title":"Vaccine"},{"key":"787_CR69","doi-asserted-by":"publisher","unstructured":"Kim ES, Park SK, Cho DSH, Youn JC, Lee HS, Lee HY, Cho HJ, Choi JO, Jeon ES, Lee SE, et al. Eligibility and cost-utility analysis of dapagliflozin in patients with heart failure across the whole spectrum of ejection fraction in South Korea. Am J Cardiovasc Drugs. 2024 Sep;24(5):311-324. https:\/\/doi.org\/10.1007\/s40256-024-00654-y.","DOI":"10.1007\/s40256-024-00654-y"},{"key":"787_CR70","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.3346\/jkms.2024.39.e8","volume":"39","author":"ES Kim","year":"2024","unstructured":"Kim ES, Park SK, Youn JC, Lee HS, Lee HY, Cho HJ, Choi JO, Jeon ES, Lee SE, Kim MS, et al. Real-World Eligibility and Cost-Effectiveness Analysis of Empagliflozin for Heart Failure in Korea. J Korean Med Sci. 2024;39:e8.","journal-title":"J Korean Med Sci"},{"key":"787_CR71","unstructured":"Ahn J, Kim Y, Shin S, Park J. Asian Collaborative Study on Cost-Effectiveness in Healthcare Decision Making. Seoul: National Evidence-based Healthcare Collaborating Agency; 2013. Report No.: NECA-A-13-011."},{"key":"787_CR72","doi-asserted-by":"publisher","unstructured":"Yoo SL, Kim DJ, Lee SM, Kang WG, Kim SY, Lee JH, Suh DC. Improving patient access to new drugs in South Korea: evaluation of the national drug formulary system. Int J Environ Res Public Health. 2019 Jan 12;16(2):288. https:\/\/doi.org\/10.3390\/ijerph16020288.","DOI":"10.3390\/ijerph16020288"},{"key":"787_CR73","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1186\/s12913-021-06919-x","volume":"21","author":"B Lee","year":"2021","unstructured":"Lee B, Bae EY, Bae S, Choi HJ, Son KB, Lee YS, Jang S, Lee TJ. How can we improve patients\u2019 access to new drugs under uncertainties? South Korea\u2019s experience with risk sharing arrangements. BMC Health Serv Res. 2021;21:967.","journal-title":"BMC Health Serv Res"},{"key":"787_CR74","unstructured":"National Institute for Health and Care Excellence (NICE). What is NICE\u2019s severity modifier? [Internet]. London: NICE; 2024. Available from: https:\/\/indepth.nice.org.uk\/what-is-nices-severity-modifier\/index.html."},{"key":"787_CR75","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.jval.2023.05.015","volume":"26","author":"A Angelis","year":"2023","unstructured":"Angelis A, Harker M, Cairns J, Seo MK, Legood R, Miners A, Wiseman V, Chalkidou K, Grieve R, Briggs A. The Evolving Nature of Health Technology Assessment: A Critical Appraisal of NICE\u2019s New Methods Manual. Value Health. 2023;26:1503\u20139.","journal-title":"Value Health"},{"key":"787_CR76","doi-asserted-by":"publisher","first-page":"100156","DOI":"10.1016\/j.hpopen.2025.100156","volume":"10","author":"A Wailoo","year":"2025","unstructured":"Wailoo A, Gorrod HB, Dunning L, Kenny J, Leckenby E, Shah K. The NICE experience of designing and utilising severity weights. Health Policy Open. 2025;10:100156.","journal-title":"Health Policy Open"},{"key":"787_CR77","doi-asserted-by":"publisher","first-page":"e833","DOI":"10.1016\/S2214-109X(23)00162-6","volume":"11","author":"A Pichon-Riviere","year":"2023","unstructured":"Pichon-Riviere A, Drummond M, Palacios A, Garcia-Marti S, Augustovski F. Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures. Lancet Global Health. 2023;11:e833\u201342.","journal-title":"Lancet Global Health"},{"key":"787_CR78","doi-asserted-by":"publisher","first-page":"e0206121","DOI":"10.1371\/journal.pone.0206121","volume":"13","author":"E-Y Bae","year":"2018","unstructured":"Bae E-Y, Kim HJ, Lee H-J, et al. Role of economic evidence in coverage decision-making in South Korea. PLoS ONE. 2018;13:e0206121.","journal-title":"PLoS ONE"},{"key":"787_CR79","unstructured":"Health Insurance Review and Assessment Service (HIRA). First publication of ICER results for drugs submitted for economic evaluation since the introduction of the drug screening system [Internet]. Wonju: HIRA; 2019 Dec 30. Available from: https:\/\/www.hira.or.kr\/bbsDummy.do?brdBltNo=10774&brdScnBltNo=4&pageIndex=1&pageIndex2=1&pgmid=HIRAA020041000100#none."},{"key":"787_CR80","unstructured":"Health Insurance Review and Assessment Service (HIRA). Announcing the 2018-2022 ICERs for Agents Submitting Economic Assessments [Internet]. Wonju: HIRA; 2023 Dec 28. Available from: https:\/\/www.hira.or.kr\/bbsDummy.do?pgmid=HIRAA020002000100&brdScnBltNo=4&brdBltNo=10648#none."},{"key":"787_CR81","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/14737167.2024.2410250","volume":"25","author":"TJ Lee","year":"2025","unstructured":"Lee TJ, Son KB. Perceptions of risk sharing agreements in South Korea from the viewpoints of key stakeholders: a convergent parallel mixed approach. Expert Rev Pharmacoecon Outcomes Res. 2025;25:235\u201343.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"787_CR82","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1080\/14737167.2017.1276828","volume":"17","author":"E-S Kim","year":"2017","unstructured":"Kim E-S, Kim J-A, Lee E-K. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007\u20132016 in South Korea. Expert Rev PharmacoEcon Outcomes Res. 2017;17:401\u20139.","journal-title":"Expert Rev PharmacoEcon Outcomes Res"},{"key":"787_CR83","first-page":"479","volume":"21","author":"S Kim","year":"2020","unstructured":"Kim S, Kim J, Cho H-S, Lee K, Ryu C, Lee JH. Trends in the pricing and reimbursement of new anticancer drugs in South Korea: an analysis of listed anticancer drugs during the past three years. Expert Rev PharmacoEcon Outcomes Res. 2020;21:479\u201388.","journal-title":"Expert Rev PharmacoEcon Outcomes Res"}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-026-00787-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-026-00787-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-026-00787-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:00:58Z","timestamp":1787670058000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12962-026-00787-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["787"],"URL":"https:\/\/doi.org\/10.1186\/s12962-026-00787-0","relation":{},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"18 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This study used only publicly available data and did not involve human participants.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study sponsor had no role in study design; in the data collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the paper for publication.","order":3,"name":"Ethics","label":"Role of the funder","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"109"}}